Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2036
15/01/2024 17:17
Jan 15 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN
PATENT
COVERING MASITINIB UNTIL 2036 IN THE TREATMENT OF MASTOCYTOSIS
* THIS NEW EUROPEAN PATENT PROVIDES INTELLECTUAL PROPERTY
PROTECTION FOR MASITINIB IN THIS INDICATION UNTIL OCTOBER 2036
* SAME MEDICAL USE PATENT STRATEGY HAD BEEN SUCCESSFULLY
PURSUED
IN AMYOTROPHIC LATERAL SCLEROSIS, WITH PATENT GRANTED WORLDWIDE
UNTIL 2037, AND IS BEING PURSUED IN OTHER INDICATIONS SUCH AS
MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE FOR PROTECTION UNTIL
2041, AND IN PROSTATE CANCER UNTIL 2042
Source text for Eikon: ID:nGNE1RPr4V
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease